Drug Approvals and Withdrawals Over the Last 60 Years

Author:

Abstract
The overarching theme of the current series of columns is drug development in psychiatry and the implications of the human genome project. Past columns have pointed out how pharmacogenetics and pharmacogenomics have accelerated drug development by identifying both desired targets and targets to be avoided (see http://www.preskorn.com). Scientists in drug discovery can use this information to design molecules with novel efficacy and improved safety and tolerability. Research in molecular biology and more traditional medicinal chemistry has also led to the development of “high throughput” screening technology, which allows drug discoverers to screen hundreds of thousands of molecular entities against all known human regulatory proteins of interest to develop more refined structure-activity relationships to guide drug synthesis. With regard to improved safety, an earlier column in this series pointed out that certain widely used antidepressants such as fluoxetine and paroxetine would not be likely even to make it out of drug discovery today given our improved ability to design drugs to avoid unintended inhibition of cytochrome P450 enzymes. 1 In terms of novel efficacy, earlier columns have pointed out the number of brain-specific regulatory proteins that have been identified as a result of the human genome project. 2,3 Once identified and characterized, these regulatory proteins can become targets for developing drugs that affect specific central nervous system (CNS) functions. Such drug development has the potential to vastly increase the number of CNS drugs brought to market as well as the number of new indications for drugs. To put these advances in perspective, this column will review the number of drugs approved and withdrawn per year in the United States during the second half of the 20th century. The black box warning recently given to nefazodone due to drug-induced liver failure will also be discussed along with the potential role of pharmacogenomics research in salvaging such drugs for the majority of patients who could benefit from the drug without risk of this rare serious adverse event. This column will point out limitations of the drug development and approval process. However, these comments require a context in which to be understood. In this regard, the words of Winston Churchill come to mind when he commented that democracy was a terrible form of government except when compared to all other forms of government. The drug development process in the United States and the other G7 countries is a business. That has consequences. Perhaps, the most important is that it has resulted in tremendous breakthroughs in the ability to treat and cure many, many diseases. That would likely not be the case if there was no incentive to risk the capital needed to do such groundbreaking work. Consider that few, if any drugs, have been developed by any government. The number of drugs approved and withdrawn is relevant to an issue that has been addressed periodically in this column, drug-drug interactions (DDIs) and their implications for the practitioner and the health care system in general (see http://www.preskorn.com for a list of relevant columns and publications). As the number of available prescription and over-the-counter (OTC) drugs and herbal products increases, the number of potential types of DDIs increases as a factorial of the number of marketed drugs that can be used in combination. Thus, the number of new drugs entering the market per year puts a strain on prescribers’ ability to stay current concerning the pharmacology of the individual drug and its potential DDIs. This issue is particularly vexing because DDIs occur across therapeutic classes.